<DOC>
	<DOCNO>NCT00815347</DOCNO>
	<brief_summary>Hypothesis : The endothelin-1 receptor antagonist , bosentan add treatment asthma patient symptomatic despite use controller therapy improve asthma symptom physiology . Twenty patient diagnosis asthma , age 21 70 symptomatic despite use least one controller medication randomize either placebo active medication 8 week period ( initial 4 week 1/2 final dose per package insert FDA approval ) . Measures lung function symptom record . Patients cross , patient initially placebo receive active drug 8 week initially active drug receive placebo . The endpoint measure . The acute bronchodilator effect drug also test first day therapy full therapeutic dose .</brief_summary>
	<brief_title>Bosentan Poorly Controlled Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Diagnosis asthma , maintain minimum 1 antiinflammatory/controller daily long act Bagonist therapy inadequate control symptom . ( Defined symptom include wheezing , chest tightness shortness breath occur least 3 time week require use `` rescue '' shortacting Bagonist least 3 time week ) . FEV1 le 80 % predict great 40 % screen visit . A minimum 12 % reversibility FEV1 albuterol screen visit previously document prior two year . Women childbearing potential must use 2 nonhormonal method birth control ( 2 method subject partner ) study 1 month last dose study medication . Male subject must use two non hormonal method birth control ( 2 method subject partner ) study 1 month last dose study medication . History liver disease , clinically significant cardiac disease , renal disease pulmonary disease asthma . Patients clinically significant laboratory abnormality LFTs/bilirubin ( AST/ALT , TBili , alkaline phosphatase ) clinically significant anemia exclude . Clinically significant anemia define anemia result serum Hgb 1 gm/dl LLN , Patients isolate minimal elevation bilirubin ( eg . occur Gilbert 's disease ) minimal elevation transaminase ( less 1.2 x ULN ) without history liver disease , risk factor liver disease symptom liver disease may still include study investigator 's discretion , LFT test study visit . ) Cigarette history &gt; 10 pack year . Predicted inability adhere medication regimen documentation requirement study ( symptom medication diary ) . Respiratory infection 30 day precede screen visit . Requirement change schedule asthma medication use , include oral steroid dose change , acute medical care asthma 30 day precede screen visit . Predicted inability safely refrain Bagonist use require amount time study visit day . Use tiotropium Pregnancy , breast feeding use hormonal method birth control mean birth control study . Use potent CYP3A4 CYP2C9 inhibitor , include , limited azole antifungal , amiodarone , glyburide , warfarin , cyclosporine , ritonavir , medication potentially toxic liver bone marrow . Use illegal drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Asthma</keyword>
</DOC>